Enoticumab
Cat. No.: A883
Featured
Chemical Structure
1192578-27-0
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively.
| Cas No.: |
1192578-27-0 |
| pH value: |
Corresponds to reference standard: PASS |
| Non-reduced CE-SDS: |
>95% |
| SEC-HPLC: |
>95% |
| Isoelectric Point: |
Corresponds to reference standard |
| Osmolality: |
Corresponds to reference standard: PASS |
| Peptide mapping: |
Corresponds to reference standard: PASS |
| N-terminal sequence: |
Corresponds to reference standard: PASS |
Get Quote
